Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022
Athira Pharma, a late clinical-stage biopharmaceutical company, announced it will report its financial results for Q4 and full year 2021 on March 24, 2022. The conference call to discuss these results will start at 4:30 PM ET. Athira focuses on developing small molecules to enhance neuronal health and combat neurodegeneration, with its lead candidate, fosgonimeton (ATH-1017), targeting Alzheimer’s and Parkinson’s diseases. For more details, visit their website.
- Athira is advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), targeting Alzheimer’s and Parkinson’s disease.
- The upcoming financial results announcement highlights the company's progress and transparency.
- The lack of financial data in the PR may raise investor concerns about the company's performance.
BOTHELL, Wash., March 17, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and provide a business update on Thursday, March 24, 2022 following the close of the U.S. financial markets. Athira will host a conference call to discuss these results on Thursday, March 24, 2022 at 4:30 pm Eastern time (1:30 pm Pacific time).
In order to participate in the conference call, please dial 833-614-1520 (domestic) or 516-575-8710 (international) and refer to conference ID 3597642. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.athira.com, where it will also be archived.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule for Alzheimer’s and Parkinson’s disease dementia and Dementia with Lewy bodies. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.
Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219
FAQ
When will Athira Pharma announce its Q4 and full year 2021 financial results?
What time is Athira Pharma's conference call?
What is the stock symbol for Athira Pharma?
What is the focus of Athira Pharma's research?
